Etex Corp. inked a distribution deal with Stryker Corp. (NYSE:SYK) for a pair of its private-label bone graft substitute products.
The Cambridge, Mass.-based biomaterials firm signed a non-exclusive distribution deal for Stryker’s spine division to market and sell Etex’s Bio MatrX Structure and Bio MatrX Generate products. Both products incorporate Etex’s nanocrystalline calcium phosphate bone putty.
Kalamazoo, Mich.-based Stryker isn’t the first company to sell Etex‘s calcium phosphate bone-grafting technology. In January, Etex signed another non-exclusive distribution agreement for the bone putty with Warsaw, Ind.-based OrthoPediatrics Corp.
Etex describes ithe products as “synthetic bone graft substitutes that set hard upon implantation” and create a osteo-conductive scaffold that facilitates new bone growth, according to a press release. The company also manufactures EquivaBone, a moldable, injectable putty made of the nanocrystalline calcium phosphate and demineralized bone matrix used in posterolateral spine fusion procedures; Beta-bsm, an injectable paste; and a moldable putty called Gamma-bsm. The latter two are also designed to create a scaffold to promote new bone growth.
